Pharming Group NV
AEX:PHARM
Pharming Group NV
Total Equity
Pharming Group NV
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pharming Group NV
AEX:PHARM
|
Total Equity
$277.1m
|
CAGR 3-Years
11%
|
CAGR 5-Years
9%
|
CAGR 10-Years
28%
|
|
|
ProQR Therapeutics NV
NASDAQ:PRQR
|
Total Equity
€57.1m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-5%
|
|
|
Uniqure NV
NASDAQ:QURE
|
Total Equity
$198.9m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
5%
|
|
|
argenx SE
XBRU:ARGX
|
Total Equity
$6.1B
|
CAGR 3-Years
29%
|
CAGR 5-Years
29%
|
CAGR 10-Years
65%
|
|
|
Merus NV
NASDAQ:MRUS
|
Total Equity
$775m
|
CAGR 3-Years
37%
|
CAGR 5-Years
56%
|
CAGR 10-Years
35%
|
|
|
LAVA Therapeutics NV
NASDAQ:LVTX
|
Total Equity
$28m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
37%
|
CAGR 10-Years
N/A
|
|
Pharming Group NV
Glance View
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company is headquartered in Leiden, Zuid-Holland and currently employs 321 full-time employees. The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
See Also
What is Pharming Group NV's Total Equity?
Total Equity
277.1m
USD
Based on the financial report for Dec 31, 2025, Pharming Group NV's Total Equity amounts to 277.1m USD.
What is Pharming Group NV's Total Equity growth rate?
Total Equity CAGR 10Y
28%
Over the last year, the Total Equity growth was 25%. The average annual Total Equity growth rates for Pharming Group NV have been 11% over the past three years , 9% over the past five years , and 28% over the past ten years .
